Skip to main content
GutCited

Saccharomyces boulardii Figures

15 figures issues de recherches évaluées par des pairs

Tous Psyllium Husk Bifidobacterium lactis Fructooligosaccharides (FOS) Lactobacillus plantarum Peppermint Oil Pancreatic Enzymes (Pancrelipase) Curcumin Vitamin A Medium-Chain Triglycerides (MCT Oil) Galactooligosaccharides (GOS) Lactobacillus gasseri Aloe Vera (Inner Leaf Gel) Alpha-Galactosidase Vitamin D L-Glutamine Inulin Ginger Lactase Berberine Omega-3 Fatty Acids (EPA/DHA) Bovine Colostrum Zinc Bifidobacterium bifidum Butyrate (Sodium/Calcium Butyrate) Bacillus coagulans Saccharomyces boulardii Lactobacillus acidophilus N-Acetyl Cysteine (NAC) Bifidobacterium longum
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Fig 1. PRISMA flow diagram of evaluated studies for randomized controlled trials for efficacy of specific probiotics for the prevention or treatment of various diseases, searched from inception of databases to June 2018. Outcomes were extracted from rando
Figure 2 Flowchart

A PRISMA flow diagram details the systematic literature search and study selection process for evaluating probiotic efficacy across multiple clinical conditions. Studies are screened from inception through defined databases with specific inclusion and exclusion criteria.

Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

Fig 2. Clinical decision algorithm for choosing an appropriate probiotic product. https://doi.org/10.1371/journal.pone.0209205.g002
Figure 3 Flowchart

A clinical decision algorithm guides clinicians through the process of selecting an appropriate probiotic product based on the patient's specific condition, available evidence for particular strains, and practical considerations such as product availability and cost.

Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

Figure 2
Figure 2 Diagram

Approaches for managing antibiotic-associated dysbiosis are summarized, including strategies to restore gut microbial diversity after antibiotic treatment. The figure outlines interventions such as probiotics and microbiota-targeted therapies that may help mitigate dysbiosis in populations predisposed to gut disruption.

Current understanding of antibiotic-associated dysbiosis and approaches for its management.

Figure 2
Figure 2 Diagram

Illustration of Saccharomyces boulardii CNCM I-745 mechanisms of action in the intestinal lumen, showing direct antimicrobial effects and pathogen binding at the gut epithelial surface.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 3
Figure 3 Diagram

Schematic depicting how S. boulardii CNCM I-745 modulates intestinal epithelial barrier function, including tight junction protein preservation and mucus secretion enhancement.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 4
Figure 4 Diagram

Schematic depicting how S. boulardii CNCM I-745 modulates intestinal epithelial barrier function, including tight junction protein preservation and mucus secretion enhancement.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 5
Figure 5 Diagram

Diagram of S. boulardii's immunomodulatory actions in the gut, illustrating effects on secretory IgA production, anti-inflammatory cytokine release, and immune cell regulation.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 6
Figure 6 Diagram

Diagram of S. boulardii's immunomodulatory actions in the gut, illustrating effects on secretory IgA production, anti-inflammatory cytokine release, and immune cell regulation.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 7
Figure 7 Diagram

Evidence summary for S. boulardii CNCM I-745 efficacy against specific intestinal pathogens including Clostridium difficile, showing toxin neutralization and receptor binding inhibition mechanisms.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 8
Figure 8 Diagram

Evidence summary for S. boulardii CNCM I-745 efficacy against specific intestinal pathogens including Clostridium difficile, showing toxin neutralization and receptor binding inhibition mechanisms.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 9
Figure 9 Diagram

Overview of enzymatic activities of S. boulardii relevant to intestinal infection defense, including protease secretion that degrades bacterial toxins and virulence factors.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 10
Figure 10 Diagram

Overview of enzymatic activities of S. boulardii relevant to intestinal infection defense, including protease secretion that degrades bacterial toxins and virulence factors.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 5
Figure 5 Diagram

Clinical applications of S. boulardii across various gastrointestinal conditions are summarized, reflecting its established effectiveness in acute diarrhea treatment and prevention.

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system.

Figure 6
Figure 6 Diagram

A comprehensive model of S. boulardii's multifaceted interactions with host immunity and intestinal microbiota is presented, integrating molecular and clinical evidence.

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system.

Figure 1
Figure 1

Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding …